ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review
05 mai 2022 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In...
ARCA biopharma Announces First Quarter 2022 Financial Results
02 mai 2022 16h15 HE
|
ARCA biopharma, Inc.
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE...
ARCA biopharma Establishes Special Committee of the Board of Directors
18 avr. 2022 16h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
04 janv. 2022 08h30 HE
|
ARCA biopharma, Inc.
Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important...
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
16 sept. 2021 08h30 HE
|
ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th
16 août 2021 08h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2
09 août 2021 08h00 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update
04 août 2021 16h15 HE
|
ARCA biopharma, Inc.
Phase 2b clinical trial evaluating rNAPc2 as a potential treatment for COVID-19 expanded to South AmericaTopline data anticipated in the fourth quarter of 2021 WESTMINSTER, Colo., Aug. 04, 2021 ...
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
13 juil. 2021 08h00 HE
|
ARCA biopharma, Inc.
rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTrial expanded to South America, with regulatory approvals for Argentina and BrazilTarget trial enrollment...
ARCA biopharma to Present at Access to Giving Virtual Investor Conference on July 13th
09 juil. 2021 08h00 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., July 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...